We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||2.17 - 2.30|
|52 Week Range||1.70 - 3.60|
|PE Ratio (TTM)||25.00|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.58|
LONDON, UK / ACCESSWIRE / May 17, 2018/ If you want a free Stock Review on BLRX sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com evaluates Aratana Therapeutics Inc. (NASDAQ: PETX), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and BioLine Rx Ltd (NASDAQ: BLRX).
BioDelivery Sciences International, Inc. (BDSI) today announced that it has entered into an agreement with an affiliate of Broadfin Capital LLC (Broadfin), a large BDSI stockholder, to reconstitute BDSI’s Board of Directors and to significantly strengthen BDSI’s financial position. The closing of this agreement is subject to and effective upon the closing of BDSI’s $50 million equity financing announced earlier today.
The Series B Stock is being sold for $10,000 per share, and each share of Series B Stock will be convertible into a number of shares of BDSI common stock determined by dividing $10,000 by $1.80. Although BDSI will receive the proceeds of the offering at closing, the Series B Stock will not be convertible into common stock until BDSI receives stockholder approval of the transaction for Nasdaq Stock Market purposes as well as stockholder approval of an increase in BDSI’s authorized shares of common stock.
On a per-share basis, the Raleigh, North Carolina-based company said it had a loss of 18 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
BELBUCA ® Net Revenues Increased 76% Over 1 Q17 Achieved Significant Prescription Growth Increase of 55% for BELBUCA in 1 Q18 vs 1 Q17 Achieved Company Total Net Revenue of $11.3 Million for 1 Q18 Addition ...
Endocyte (ECYT) is expected to provide updates on pipeline candidates when it reports first-quarter 2018 results on May 9 after the market closes.
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
People Also Watch
|Symbol||Last Price||Change||% Change|
BioCryst Pharmaceuticals, Inc.
Amicus Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc.
Vanda Pharmaceuticals Inc.
|Initiated||Seaport Global : to Buy||1/26/2018|
|Upgrade||Cantor Fitzgerald : to Overweight||5/17/2017|
|Upgrade||Janney Capital : to Buy||9/23/2016|
|Downgrade||Cantor Fitzgerald : to Hold||5/11/2016|
|Initiated||Cantor Fitzgerald : to Buy||11/4/2015|
|Initiated||Cantor Fitzgerald : to Buy||4/8/2015|
Industry : Biotechnology
Full Time Employees : 115
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.